SMITH & NEPHEW PLC
11 November 2024
NOTIFICATION AND PUBLIC DISCLOSURE IN ACCORDANCE WITH THE REQUIREMENTS OF THE EU MARKET ABUSE REGULATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES ("PDMR") AND PERSONS CLOSELY ASSOCIATED WITH THEM.
| Reason for the notification | |
| Initial notification /Amendment | Initial notification |
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| Name | Smith & Nephew plc |
| LEI | 213800ZTMDN8S67S1H61 |
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| Description of the financial instrument, type of instrument | Smith & Nephew plc ordinary shares of USD 0.20 each |
| Identification code | ISIN: GB0009223206 |
| Nature of the transaction | Purchase of ordinary shares through the Company's Dividend Re-Investment Plan following the 2024 interim dividend payment on 8 November 2024. |
| Date of Transaction | 2024 - 11 - 08 |
| Place of Transaction | London Stock Exchange (XLON) |
| Name (Position) | Director / PDMR | Price | Volume | Aggregated information |
| Helen Barraclough (Group General Counsel and Company Secretary) | PDMR | 9.234
| 421.23522 | N/A Single Transaction |
| Paul Connolly (President, Global Operations) | PDMR | 9.234
| 194.91162
| N/A Single Transaction |
| Phil Cowdy Chief Corporate Development & Corporate Affairs Officer | PDMR | 9.234
| 1.9035 | N/A Single Transaction |
| Mizanu Kebede (Chief Quality & Regulatory Affairs Officer) | PDMR | 9.234
| 111.64316
| N/A Single Transaction |
| Deepak Nath (Chief Executive Officer) | Director | 9.234
| 1924.20518
| N/A Single Transaction |
| Scott Schaffner (President, Sports Medicine) | PDMR | 9.234
| 794.95718 | N/A Single Transaction |
Helen Barraclough
General Counsel and Company Secretary
Smith & Nephew plc
Tel: +44 (0)1923 477100
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.